Publication:
Assessing the value of moderate‐to‐severe atopic dermatitis treatment using multi‐criteria decision analysis (MCDA)

dc.contributor.authorPereyra-Rodriguez, Jose Juan
dc.contributor.authorPoveda, José Luis
dc.contributor.authorRivero, Alvaro
dc.contributor.authorSerra-Baldrich, Esther
dc.contributor.authorSilvestre, Juan Francisco
dc.contributor.authorArmario-Hita, José Carlos
dc.contributor.authorCalleja, Miguel Angel
dc.contributor.authorCarrascosa, Jose Manuel
dc.contributor.authorFlorez, Angeles
dc.contributor.authorHerranz, Pedro
dc.contributor.authorComellas, Marta
dc.contributor.authorOrtiz de Frutos, Francisco Javier
dc.contributor.authoraffiliation[Pereyra-Rodríguez,JJ] Dermatology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
dc.contributor.authoraffiliation[Armario-Hita,JC] Dermatology Department, Hospital Universitario de Puerto Real, University of Cádiz, Cádiz, Spain.
dc.contributor.authoraffiliation[Carrascosa,JM] Pharmacy Department, Hospital Universitario Virgen Macarena, Sevilla, Spain.
dc.date.accessioned2025-06-10T08:47:50Z
dc.date.available2025-06-10T08:47:50Z
dc.date.issued2024-01-01
dc.description.abstractThe increased understanding of atopic dermatitis (AD) pathophysiology has shed light on the underlying immunologic mechanisms and spurred the development of novel, more precisely targeted therapies. As new agents become available, assessing their added value is advisable. Yet the value of novel health interventions sometimes remains largely unmeasured and inadequately understood. Value assessment is challenging since it involves assessing the extent to which it meets current unmet needs. Therefore, it is necessary to establish the most relevant health outcomes from different stakeholders' perspectives.
dc.description.versionYes
dc.identifier.citationPereyra‐Rodríguez JJ, Poveda JL, Rivero A, Serra‐Baldrich E, Silvestre JF, Armario‐Hita JC et al. Assessing the value of moderate‐to‐severe atopic dermatitis treatment using multi‐criteria decision analysis (MCDA). JEADV 2024;38:e59‐e62
dc.identifier.doi10.1111/jdv.19432
dc.identifier.issn0926-9959
dc.identifier.pmid37594914
dc.identifier.urihttps://hdl.handle.net/10668/28520
dc.issue.number1
dc.journal.titleJournal of the European Academy of Dermatology and Venereology
dc.language.isoen
dc.page.numbere59-e62
dc.publisherWiley
dc.relation.publisherversionhttps://onlinelibrary.wiley.com/doi/10.1111/jdv.19432
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectAtopic dermatitis
dc.subjectMulti‑criteria decision analysis (MCDA)
dc.subjectHealth-related quality of life (HRQoL)
dc.subjectPruritus reduction
dc.subjectDisease activity control
dc.subject.decsDermatitis atópica
dc.subject.decsAnálisis de decisión multicriterio
dc.subject.decsCalidad de vida relacionada con la salud
dc.subject.decsReducción del prurito
dc.subject.decsControl de la actividad de la enfermedad
dc.subject.meshDecision Making
dc.subject.meshDecision Support Techniques
dc.subject.meshDermatitis, Atopic
dc.titleAssessing the value of moderate‐to‐severe atopic dermatitis treatment using multi‐criteria decision analysis (MCDA)
dc.typeletter
dc.type.hasVersionAM
dc.volume.number38
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
MCDA_JEADV.pdf
Size:
342.87 KB
Format:
Adobe Portable Document Format